Naval Daver, MD, The University of Texas MD Anderson Cancer Center, Houston, TX; Joshua Zeidner, MD, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC; Eytan Stein, MD, Memorial Sloan Kettering Cancer Center, New York City, NY; and Amir Fathi, MD, MPH, Massachusetts General Hospital, Boston, MA, explore how menin inhibitors, especially revumenib and ziftomenib, are being integrated into AML treatment by combining them with agents like azacitidine, venetoclax, and intensive chemotherapy to boost response rates. They also discuss resistance mechanisms (such as clonal evolution and on-target mutations), challenges in durability of response, and strategic directions for safety monitoring and future clinical trial designs.